The global Immunoglobulins Market is becoming increasingly important within the biopharmaceutical industry as healthcare systems respond to the growing burden of immunodeficiency disorders, autoimmune diseases, and inflammatory conditions. Immunoglobulins, commonly known as antibodies, play a critical role in immune defense and are used therapeutically when patients require antibody replacement or immune modulation.
According to Kings Research, the global immunoglobulins market was valued at USD 15.65 billion in 2023 and is projected to grow from USD 16.75 billion in 2024 to USD 28.81 billion by 2031, registering a CAGR of 8.06% from 2024 to 2031. The expansion is being supported by increasing diagnosis of immune disorders, a growing geriatric population, broader clinical applications, and improvements in healthcare infrastructure.
The market covers several product categories, including immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), and other formulations. Products are administered through intravenous, subcutaneous, or intramuscular routes depending on the therapeutic requirement and patient condition.
Rising Prevalence of Immunodeficiency and Autoimmune Disorders
The increasing prevalence and recognition of immunodeficiency and autoimmune diseases are among the most important growth factors for the Immunoglobulins Market.
Patients with primary immunodeficiency diseases may have insufficient antibody production and therefore require immunoglobulin replacement therapy. Secondary immunodeficiencies associated with conditions such as cancer, HIV, or immunosuppressive treatments can also increase demand for antibody-based therapies.
At the same time, immunoglobulins are being used for a growing range of autoimmune and inflammatory disorders. Conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), and Guillain-Barré syndrome have contributed to broader clinical applications.
This expanding therapeutic role is helping immunoglobulin products move beyond traditional replacement therapy toward a wider range of immune-modulating applications.
IgG Remains a Major Product Segment
Among product types, IgG represents a particularly important segment of the market. The IgG segment generated approximately USD 6.79 billion in revenue in 2023, supported by its widespread application in the management of immunodeficiency and autoimmune disorders.
IgG products are available in multiple formulations and can be administered through different routes depending on the patient's needs. Their established clinical use and broad therapeutic applicability make them an important component of immunoglobulin treatment.
The development of improved formulations is also helping manufacturers address patient convenience, safety, tolerability, and treatment frequency. This is encouraging innovation in both intravenous and subcutaneous products.
Intravenous Immunoglobulin Maintains a Strong Position
The intravenous segment accounted for 47.53% of the immunoglobulins market in 2023. Kings Research projects that the segment will reach approximately USD 13.16 billion by 2031.
Intravenous immunoglobulin, or IVIG, is widely used when a relatively rapid therapeutic effect is required. It has become an established treatment option for several immunodeficiency, neurological, hematological, and autoimmune conditions.
The route also provides healthcare professionals with greater control over dosing in clinical settings. Hospitals and specialized treatment centers therefore remain important channels for IVIG administration.
At the same time, subcutaneous immunoglobulin therapy is gaining attention because it can offer greater flexibility for suitable patients. The development of home-based and patient-managed treatment models could influence the market's administration landscape over the coming years.
Advances in Plasma Fractionation Improve Manufacturing
One of the most important technological trends in the immunoglobulins industry is the advancement of plasma fractionation technologies.
Immunoglobulin products are primarily derived from human plasma, making efficient plasma collection, purification, fractionation, and quality control essential to maintaining supply.
Modern manufacturing processes increasingly use advanced chromatography, filtration technologies, and automated processing systems. These technologies can improve product yield, purity, safety, and manufacturing consistency while helping producers manage increasingly complex production requirements.
The development of more efficient fractionation processes is particularly important because demand for plasma-derived therapies continues to increase. Manufacturers are therefore investing in production capacity and technologies designed to improve the utilization of collected plasma.
In November 2023, Grifols received FDA approval for a new immunoglobulin purification and filling facility in Clayton, North Carolina. The facility was expected to increase the company's global Gamunex-C production capacity to approximately 60 million grams annually.
New Formulations Expand Treatment Options
Innovation in immunoglobulin formulations is another important area of market development. Pharmaceutical companies are working on formulations that can improve convenience, safety, and patient experience.
In September 2024, GC Biopharma USA launched ALYGL, an FDA-approved 10% intravenous immunoglobulin therapy for adults with primary humoral immunodeficiency. The product uses a purification process designed to reduce coagulation factor XIa to undetectable levels.
Similarly, in January 2024, Takeda announced FDA approval of GAMMAGARD LIQUID as an intravenous immunoglobulin therapy for adults with CIDP.
These developments illustrate the industry's focus on improving established immunoglobulin therapies while expanding their applications across different patient populations.
Growing Clinical Applications Create New Opportunities
The therapeutic scope of immunoglobulins continues to expand. Beyond primary immunodeficiency, these therapies are increasingly being evaluated and used in autoimmune, neurological, hematological, and inflammatory conditions.
For example, immunoglobulin therapy has been investigated in patients receiving newer cancer therapies. Kings Research cites an analysis reported by the American Association for Cancer Research in September 2023 in which IVIg treatment was associated with a reduction in severe infections among a small group of multiple myeloma patients receiving anti-BCMA bispecific antibody therapy.
The expanding use of immunoglobulins demonstrates the importance of these therapies within increasingly complex treatment pathways. As researchers better understand immune mechanisms, additional opportunities may emerge for antibody-based treatment and immune modulation.
High Production Costs Remain a Major Challenge
Despite strong growth prospects, the Immunoglobulins Market faces significant supply and affordability challenges.
Producing immunoglobulin therapies is complex because the products depend on human plasma collection followed by multiple purification and quality-control stages. Plasma collection itself requires specialized facilities, donor recruitment, testing, storage, and transportation.
These factors contribute to high manufacturing and logistical costs. In addition, reimbursement policies differ substantially between countries, affecting patient access to treatment.
Kings Research identifies the high cost of immunoglobulin therapies as a significant market constraint, particularly in resource-limited healthcare systems. Manufacturers are therefore focusing on increasing plasma collection capacity, improving production efficiency, and investing in advanced manufacturing technologies.
Biosimilar and alternative therapeutic approaches may also contribute to improving affordability over the longer term.
North America Leads the Immunoglobulins Market
North America held approximately 36.42% of the global immunoglobulins market in 2023. Kings Research values the regional market at around USD 5.70 billion for the year.
The region benefits from developed healthcare infrastructure, strong biopharmaceutical capabilities, established plasma collection networks, and comparatively high awareness of immunoglobulin therapies.
The United States is particularly important because of its large patient population, extensive pharmaceutical research ecosystem, and established reimbursement and specialty-care infrastructure.
The region also has a strong presence of major immunoglobulin manufacturers, which supports investment in research, manufacturing capacity, and new product development.
Asia Pacific Offers Strong Growth Potential
Asia Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 8.62% between 2024 and 2031. The regional market is forecast to reach approximately USD 6.15 billion by 2031.
Several factors are supporting this growth, including increasing healthcare expenditure, improved diagnostic capabilities, rising awareness of immune disorders, and expanding biopharmaceutical manufacturing.
China, India, Japan, South Korea, and Southeast Asian countries are investing in healthcare infrastructure and domestic pharmaceutical capabilities. Greater attention to rare diseases and immunological disorders is also creating opportunities for immunoglobulin therapies.
Government efforts to strengthen domestic plasma collection and biopharmaceutical manufacturing could become particularly important for reducing dependence on international supply chains.
In October 2024, Otsuka America Pharmaceutical announced positive interim results from its Phase 3 VISIONARY study evaluating sibeprenlimab for adults with IgA nephropathy, illustrating the continuing research activity around immunoglobulin-related diseases and immune-targeted therapies.
Regulatory Standards Shape Product Development
Because immunoglobulin products are biological medicines derived primarily from human plasma, regulatory oversight is essential for maintaining product safety, quality, and consistency.
In Australia, the National Immunoglobulin Governance Program oversees the supply and appropriate use of government-funded immunoglobulin products. The program emphasizes evidence-based utilization because immunoglobulin is a limited therapeutic resource derived from human plasma.
In Europe, the European Medicines Agency (EMA) regulates immunoglobulin therapies through guidelines covering the clinical investigation of human normal immunoglobulin for intravenous administration.
Internationally, World Health Organization guidance also supports quality and manufacturing standards for antibody-related medicinal products.
These regulatory requirements influence everything from donor screening and plasma collection to purification, formulation, testing, storage, and distribution.
Competitive Landscape
The global immunoglobulins industry features a combination of major plasma-product manufacturers, pharmaceutical companies, biotechnology firms, and regional specialists.
Key companies identified by Kings Research include Kedrion S.p.A., LFB, Shanghai RAAS Blood Products Co., Ltd., Grifols, China Biologic Products Holdings, Bio Products Laboratory, Takeda Pharmaceutical Company, Octapharma, Biotest, Eli Lilly, Pfizer, Prothya Biosolutions Netherlands, Emergent, ADMA Biologics, and Baxter.
Competition is focused on increasing plasma collection, expanding manufacturing capacity, developing improved formulations, strengthening geographic distribution, and expanding clinical applications.
Subcutaneous delivery and recombinant or next-generation antibody technologies are also creating opportunities for companies to differentiate their portfolios.
Strategic partnerships and acquisitions are another important part of the competitive environment. In April 2025, Epsilogen acquired TigaTx, combining expertise in IgE and IgA antibodies with the stated goal of developing antibody-based cancer therapeutics.
Recent Developments in Immunoglobulin-Based Therapies
The industry continues to see significant clinical development beyond conventional immunoglobulin replacement.
In April 2025, Amgen announced FDA approval of UPLIZNA (inebilizumab-cdon) for adults with Immunoglobulin G4-related disease (IgG4-RD). According to the company data cited by Kings Research, the Phase 3 MITIGATE trial demonstrated an 87% reduction in the risk of disease flares compared with placebo.
In December 2024, Genethon and Hansa Biopharma initiated a Phase 2 trial evaluating imlifidase as a pretreatment for gene therapy in adults with severe Crigler-Najjar syndrome who had pre-existing anti-AAV8 antibodies. The approach is intended to address antibody-related barriers to gene therapy eligibility.
These developments demonstrate that immunoglobulin science is increasingly connected with broader areas of biotechnology, including oncology, autoimmune disease, rare diseases, and gene therapy.
Future Outlook for the Immunoglobulins Market
The future of the Immunoglobulins Market will depend on a combination of increasing clinical demand, manufacturing innovation, plasma supply, and the development of more convenient treatment options.
As populations age and immune-related diseases become more widely diagnosed, demand for antibody-based therapies is expected to increase. At the same time, pharmaceutical companies will need to address the challenges associated with plasma availability and manufacturing costs.
Automation and advanced fractionation technologies can improve production efficiency, while expanded plasma collection networks can strengthen supply resilience. Subcutaneous therapies and home-based administration may also improve convenience for appropriate patients.
Research into new immune-targeted therapies could further broaden the role of immunoglobulin-related technologies in rare diseases, autoimmune disorders, cancer, and advanced therapeutic platforms.
With the market projected to reach USD 28.81 billion by 2031, immunoglobulin products are expected to remain an important component of the global biopharmaceutical industry.
Conclusion
The Immunoglobulins Market is expanding as healthcare providers increasingly rely on antibody-based therapies to manage immunodeficiency, autoimmune, neurological, and inflammatory conditions. The rising prevalence and improved diagnosis of these disorders are creating sustained demand for immunoglobulin products.
IgG remains a major product category, while intravenous administration continues to account for a substantial share of the market. At the manufacturing level, advances in plasma fractionation, purification, filtration, and automation are helping companies improve production efficiency and product quality.
North America currently represents the largest regional market, while Asia Pacific is projected to experience the fastest growth through 2031. However, high treatment costs, plasma availability, and differences in reimbursement remain important considerations.
As biopharmaceutical companies expand manufacturing capacity and develop improved formulations and delivery methods, the industry is moving toward a more diversified and technologically advanced immunoglobulin ecosystem. Continued innovation in plasma-derived therapies and immune-targeted biotechnology is expected to shape the market's next phase of development.
You must be logged in to post a comment.